Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 15/20 | 0.47 |
| ▸ | PPARA | Q07869 | 13/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715966 | 0.93 | GCG (0.49) | GCGPPARGPPARAPPARDTRPV1 | |
| SCHEMBL6713208 | 0.93 | GCG (0.48) | GCGPPARGPPARAPPARDMMP9 | |
| SCHEMBL6718747 | 0.92 | GCG (0.48) | GCGPPARGPPARAHPGDSPPARD | |
| SCHEMBL6715146 | 0.90 | GCG (0.53) | GCGPPARGPPARAPPARDTRPV1 | |
| SCHEMBL6713214 | 0.89 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL6715250 | 0.89 | PPARG (0.47) | GCGPPARGPPARAPPARD | |
| SCHEMBL6715242 | 0.89 | PPARG (0.47) | GCGPPARGPPARAPPARD | |
| SCHEMBL6715252 | 0.89 | PPARG (0.47) | GCGPPARGPPARAPPARD | |
| SCHEMBL6712961 | 0.88 | GCG (0.49) | GCGPPARGPPARAPPARDHCAR2 | |
| SCHEMBL6713102 | 0.88 | GCG (0.49) | GCGPPARGPPARAPPARDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | claimed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | claimed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | GCG 78/4885PPARG 23/4885PPARA 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.